A recent analysis found a third-generation EGFR-TKI to offer superior efficacy compared with standard EGFR-TKIs in the first-line setting for EGFR-positive advanced NSCLC.

News

Long-term data from a recent trial suggest that continuation of treatment with first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) beyond EGFR-positive non-small cell lung cancer (NSCLC) progression does not improve overall survival (OS).

Read More

The American Society of Clinical Oncology (ASCO) has updated their guideline on systemic therapy for non-small cell lung cancer (NSCLC) for the first time since 2015.

Read More

The National Cancer Comprehensive Network (NCCN) has updated their treatment guidelines for non-small cell lung cancer (NSCLC) to include recommendations for BRAF mutation testing to guide therapy and a new first-line treatment option for non-squamous NSCLC.

Read More

By Reuters Staff

NEW YORK (Reuters Health) - First-line treatment with alectinib prolonged progression-free survival with less toxicity compared with crizotinib in Japanese patients with ALK-positive non-small-cell lung cancer enrolled in the J-ALEX study.

Read More

Research in Review

Adjuvant treatment with the targeted therapy gefitinib (Iressa, AstraZeneca) significantly improved disease-free survival (DFS) over standard of care after surgery for patients with non–small cell lung cancer (NSCLC), according to research that will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Selecting patients with cyclooxygenase-2 (COX-2) expression by immunohistochemistry fails to improve survival outcomes in non-small cell lung cancer (NSCLC), according to research published in the Journal of Clinical Oncology (published online May 10, 2017; doi:10.1200/JCO.2016.71.3743).

-----

Related Content

Read More

Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with crizotinib may experience increased progression-free survival (PFS) with a decrease in a type of circulating tumor cells, according to research published in Cancer Research (May 2017;77[9]:2222).

-----

Related Content

Read More

Patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) live significantly longer without disease progression when treated with a new drug compared with those treated with crizotinib.

-----

Related Content

Read More

Subscribe to Non-Small Cell Lung Cancer